SCHEMBL3006465

SCHEMBL3006465

Cc1cccc(-c2csc(N3CCN(S(=O)(=O)c4c(F)cccc4F)CC3)n2)c1C

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
AR P10275 2/20 0.58
SMN1; SMN2 Q16637 3/20 0.49
ALDH1A1 P00352 2/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
PKM P14618 7/20 0.48
PKLR P30613 4/20 0.48
KMT2A Q03164 3/20 0.48
MAPT P10636 2/20 0.48
MEN1 O00255 2/20 0.48
LMNA P02545 2/20 0.48
MAPK1 P28482 2/20 0.47
USP2 O75604 1/20 0.47
RECQL P46063 1/20 0.47
HSD17B10 Q99714 1/20 0.47
FAAH O00519 1/20 0.46
RAB9A P51151 2/20 0.44
NPC1 O15118 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3009351 0.93 AR (0.59) ARSMN1; SMN2ALDH1A1L3MBTL1PKM
SCHEMBL3015871 0.92 AR (0.50) ARSMN1; SMN2ALDH1A1L3MBTL1KMT2A
SCHEMBL3017900 0.88 MEN1 (0.47) ARSMN1; SMN2ALDH1A1L3MBTL1KMT2A
SCHEMBL3015551 0.88 AR (0.53) ARSMN1; SMN2ALDH1A1L3MBTL1PKM
SCHEMBL3011374 0.88 MEN1 (0.47) ARSMN1; SMN2ALDH1A1L3MBTL1KMT2A
SCHEMBL3012413 0.87 ALDH1A1 (0.68) ARSMN1; SMN2ALDH1A1L3MBTL1PKM
SCHEMBL3016053 0.86 AR (0.46) ARSMN1; SMN2ALDH1A1L3MBTL1PKM
SCHEMBL3018107 0.86 AR (0.58) ARSMN1; SMN2ALDH1A1L3MBTL1PKM
SCHEMBL3019779 0.85 MAPT (0.53) ARSMN1; SMN2ALDH1A1L3MBTL1PKM
SCHEMBL3650400 0.85 MEN1 (0.44) ARSMN1; SMN2ALDH1A1L3MBTL1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA AR 3801/4885SMN1; SMN2 1/4885ALDH1A1 3510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.